**Supplemental Table 1. Co-occurrence of complications at 35 years of type 1 diabetes duration in the examined EDC study cohort diagnosed in 1965-80**

|  | CAD | LEAD | DSP | CAN | ON | PR |
| --- | --- | --- | --- | --- | --- | --- |
|  | n=163 | n=163 | n=163 | n=163 | n=163 | n=163 |
|  | 24.5% | 27.6% | 63.2% | 59.5% | 36.2% | 58.3% |
|  |  |  |  |  |  |  |
| CAD |  | 12.3% | 22.1% | 20.9% | 14.7% | 19.6% |
|  Observed *n* |  | 20 | 36 | 34 | 24 | 32 |
|  Expected *n* |  | 11.0 | 25.3 | 23.8 | 14.5 | 23.3 |
|  Χ2 |  | 13.3 | 16.4 | 14.3 | 13.0 | 10.3 |
|  p-value |  | 0.0003 | <0.0001 | 0.0002 | 0.0003 | 0.001 |
|  |  |  |  |  |  |  |
| LEAD |  |  | 24.5% | 23.3% | 15.3% | 23.3% |
|  Observed *n* |  |  | 40 | 38 | 25 | 38 |
|  Expected *n* |  |  | 28.4 | 23.3 | 16.3 | 26.2 |
|  Χ2 |  |  | 17.6 | 16.0 | 10.1 | 17.5 |
|  p-value |  |  | <0.0001 | <0.0001 | 0.001 | <0.0001 |
|  |  |  |  |  |  |  |
| DSP |  |  |  | 46.6% | 31.3% | 42.9% |
|  Observed *n* |  |  |  | 76 | 51 | 70 |
|  Expected *n* |  |  |  | 61.3 | 37.3 | 60.0 |
|  Χ2 |  |  |  | 23.7 | 21.5 | 10.8 |
|  p-value |  |  |  | <0.0001 | <0.0001 | 0.001 |
|  |  |  |  |  |  |  |
| CAN |  |  |  |  | 30.7% | 44.8% |
|  Observed *n* |  |  |  |  | 50 | 73 |
|  Expected *n* |  |  |  |  | 35.1 | 56.5 |
|  Χ2 |  |  |  |  | 24.4 | 28.4 |
|  p-value |  |  |  |  | <0.0001 | <0.0001 |
|  |  |  |  |  |  |  |
| ON |  |  |  |  |  | 32.5% |
|  Observed *n* |  |  |  |  |  | 53 |
|  Expected *n* |  |  |  |  |  | 34.4 |
|  Χ2 |  |  |  |  |  | 37.9 |
|  p-value |  |  |  |  |  | <0.0001 |

CAD: Total coronary artery disease; CAN: Cardiac autonomic neuropathy; DSP: Distal symmetric polyneuropathy; LEAD: Lower extremity arterial disease; ON: Overt nephropathy; PR: Proliferative retinopathy